Evidence map›Paper›PMID 24362405›Full record

ReviewNature reviews. Immunology2014

Regulation of type I interferon responses.

Lionel B Ivashkiv, Laura T Donlin

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in Nature reviews. Immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04267809 (Modulating Endoplasmic Reticulum Stress as a Prophylactic Approach Against Symptomatic Viral Infection), which is not on this map. Cited by 2,057 papers.

0numbers the graph read from it
0cells of the map it votes in
2,057citing papers in PubMed
55.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04267809 phase2completednot on this mapstarted 2021, after this paper: background citation

Modulating Endoplasmic Reticulum Stress as a Prophylactic Approach Against Symptomatic Viral Infection

TypeinterventionalSponsorSingapore General HospitalRan2021 to 2023Enrolled32ConditionsEndoplasmic Reticulum Stress, Viral Infection, Yellow FeverArmsMetformin Hydrochloride, Calcium and Vitamin D
3 · Its place in the literature

Who cites it

2,057 citing papers in PubMed, 3,197 citations in OpenAlex.

  1. Trial
  2. Gut microbes · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Myeloid cell reprogramming drives enhanced defense againstProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Genome-scale perturbation signatures from primary human CD4bioRxiv : the preprint server for biology · 2026
    Article
  19. Article
  20. Article

1,997 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Lionel B Ivashkiv1] Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, New York 10021, USA. [2] Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, New York 10065, USA. [3] Department of Medicine, Weill Cornell Medical College, New York, New York 10065,USA.
Laura T DonlinArthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, New York 10021, USA.
Hospital for Special Surgery · US

Funding

STEROID THERAPY AND CYTOKINES IN RHEUMATIC DISEASESR01AI046712 · NIAID · HOSPITAL FOR SPECIAL SURGERY · PI IVASHKIV, LIONEL B · 2000 to 2025
$12.5M
Inhibition of STAT3 and inflammatory cytokine productionR01AI044938 · NIAID · HOSPITAL FOR SPECIAL SURGERY · PI IVASHKIV, LIONEL B · 2000 to 2025
$9.2M
CYTOKINE REGULATION OF RA SYNOVIOCYTE PHENOTYPER01AR046713 · NIAMS · HOSPITAL FOR SPECIAL SURGERY · PI IVASHKIV, LIONEL B · 1999 to 2025
$8.3M
Fc Receptors &Cytokine Balance in Rheumatoid ArthritisR01AR050401 · NIAMS · HOSPITAL FOR SPECIAL SURGERY · PI Lionel B Ivashkiv · 2004 to 2026
$7.4M
Negative Regulation of OsteoclastogenesisR01DE019420 · NIDCR · HOSPITAL FOR SPECIAL SURGERY · PI IVASHKIV, LIONEL B · 2008 to 2022
$6.0M
Macrophage and Fibroblast Crosstalk in the RA SynoviumK01AR066063 · NIAMS · HOSPITAL FOR SPECIAL SURGERY · PI DONLIN, LAURA T. · 2014 to 2018
$527k
NIAID NIH HHS R01 AI044938NIAID NIH HHS R01 AI046712NIAMS NIH HHS K01 AR066063NIAMS NIH HHS R01 AR046713NIAMS NIH HHS R01 AR050401NIDCR NIH HHS R01 DE019420
6 · The paper itself

Abstract

Type I interferons (IFNs) activate intracellular antimicrobial programmes and influence the development of innate and adaptive immune responses. Canonical type I IFN signalling activates the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway, leading to transcription of IFN-stimulated genes (ISGs). Host, pathogen and environmental factors regulate the responses of cells to this signalling pathway and thus calibrate host defences while limiting tissue damage and preventing autoimmunity. Here, we summarize the signalling and epigenetic mechanisms that regulate type I IFN-induced STAT activation and ISG transcription and translation. These regulatory mechanisms determine the biological outcomes of type I IFN responses and whether pathogens are cleared effectively or chronic infection or autoimmune disease ensues.

Indexed as

Adaptive ImmunityAnimalsAutoimmune DiseasesEpigenesis, GeneticGene Expression RegulationHumansImmunity, InnateInfectionsInterferon Type IMiceModels, ImmunologicalSignal TransductionSTAT Transcription FactorsInterferon Type ISTAT Transcription Factors

Identifiers

PMID24362405
PMCPMC4084561
OpenAlexW2000177767

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.